What are the key manufacturing challenges for cell and gene therapies?

Cell and gene therapy manufacturing faces unique challenges: 1) Autologous processing - patient-specific manufacturing (CAR-T); chain of identity critical; vein-to-vein time (3-4 weeks); limited scale-up; capacity constraints. 2) Allogeneic approaches - off-the-shelf products address scalability but face immunological barriers; gene editing for HLA knockout. 3) Viral vector production - transfection-based systems have lot-to-lot variability; stable producer cell lines emerging; limiting for gene therapies requiring high doses (1e14+ vg for DMD). 4) Quality control - potency assays challenging for complex therapies; identity testing; sterility for living products. 5) Closed processing - reduce contamination and facility classification requirements. 6) Supply chain - specialized materials (plasmids, viral vectors, GMP-grade cytokines). 7) Automation - reduce manual operations and variability; CliniMACS Prodigy, Miltenyi Tyto. 8) Cost - current costs >$300K unsustainable; platform approaches, automation, and scale addressing. Regulatory frameworks continue evolving.